Mehran Makvandi

1.8k total citations · 1 hit paper
47 papers, 1.3k citations indexed

About

Mehran Makvandi is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mehran Makvandi has authored 47 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 23 papers in Molecular Biology and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mehran Makvandi's work include PARP inhibition in cancer therapy (24 papers), DNA Repair Mechanisms (11 papers) and Neuroblastoma Research and Treatments (9 papers). Mehran Makvandi is often cited by papers focused on PARP inhibition in cancer therapy (24 papers), DNA Repair Mechanisms (11 papers) and Neuroblastoma Research and Treatments (9 papers). Mehran Makvandi collaborates with scholars based in United States, Netherlands and Germany. Mehran Makvandi's co-authors include Robert H. Mach, Kuiying Xu, Daniel A. Pryma, Chenbo Zeng, Sean W. Reilly, Catherine Hou, Chi-Chang Weng, Harrison D. Winters, Yongxiang Zheng and Roshan K. Dhungana and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Mehran Makvandi

47 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Photochemical Intermolecular [3σ + 2σ]-Cycloaddition for the Construction of Aminobicyclo[3.1.1]heptanes

2022 178 citations Mehran Makvandi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mehran Makvandi United States	20	555	496	398	235	204	47	1.3k
Dexing Zeng United States	25	384 0.7×	817 1.6×	478 1.2×	283 1.2×	189 0.9×	63	1.7k
Brian P. Lieberman United States	21	244 0.4×	559 1.1×	464 1.2×	114 0.5×	93 0.5×	46	1.4k
Janina Baranowska‐Kortylewicz United States	22	242 0.4×	487 1.0×	682 1.7×	82 0.3×	298 1.5×	79	1.4k
Stefan Wagner Germany	27	619 1.1×	740 1.5×	517 1.3×	405 1.7×	310 1.5×	89	2.1k
Christopher Cawthorne United Kingdom	22	347 0.6×	575 1.2×	321 0.8×	153 0.7×	165 0.8×	77	1.5k
Matthias Friebe Germany	20	326 0.6×	335 0.7×	681 1.7×	107 0.5×	149 0.7×	34	1.1k
Charles Truillet France	22	250 0.5×	368 0.7×	506 1.3×	90 0.4×	419 2.1×	67	1.5k
Constantin Mamat Germany	22	200 0.4×	388 0.8×	597 1.5×	511 2.2×	137 0.7×	87	1.3k
Terry L. Sharp United States	21	264 0.5×	391 0.8×	997 2.5×	65 0.3×	299 1.5×	33	1.7k
Michael Ohlmeyer United States	22	294 0.5×	1.6k 3.2×	181 0.5×	261 1.1×	98 0.5×	51	1.9k

Countries citing papers authored by Mehran Makvandi

Since Specialization

Citations

This map shows the geographic impact of Mehran Makvandi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mehran Makvandi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mehran Makvandi more than expected).

Fields of papers citing papers by Mehran Makvandi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mehran Makvandi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mehran Makvandi. The network helps show where Mehran Makvandi may publish in the future.

Co-authorship network of co-authors of Mehran Makvandi

This figure shows the co-authorship network connecting the top 25 collaborators of Mehran Makvandi. A scholar is included among the top collaborators of Mehran Makvandi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mehran Makvandi. Mehran Makvandi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Batra, Vandana, Minu Samanta, Mehran Makvandi, et al.. (2022). Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma. Clinical Cancer Research. 28(18). 4146–4157. 18 indexed citations

Lee, Hsiaoju, Sally W. Schwarz, Erin K. Schubert, et al.. (2022). The Development of ¹⁸F Fluorthanatrace: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1. Radiology Imaging Cancer. 4(1). e210070–e210070. 14 indexed citations

Xin, Yi, Maurizio Cereda, Nadir Yehya, et al.. (2022). Imatinib alleviates lung injury and prolongs survival in ventilated rats. American Journal of Physiology-Lung Cellular and Molecular Physiology. 322(6). L866–L872. 5 indexed citations

Pantel, Austin R., Varsha Viswanath, Mehran Makvandi, et al.. (2021). Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1–Targeted ¹⁸F-Fluorthanatrace PET Images of Ovarian Cancer. Journal of Nuclear Medicine. 63(1). 44–50. 14 indexed citations

Puentes, Laura N., Mehran Makvandi, & Robert H. Mach. (2021). Molecular Imaging: PARP-1 and Beyond. Journal of Nuclear Medicine. 62(6). 765–770. 24 indexed citations

Riad, Aladdin, Sarah B. Gitto, Hwan Lee, et al.. (2020). PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response. Molecules. 25(24). 6029–6029. 21 indexed citations

Makvandi, Mehran, Hwan Lee, Laura N. Puentes, et al.. (2019). Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models. Molecular Cancer Therapeutics. 18(7). 1195–1204. 39 indexed citations

Elmi, Azadeh, Mehran Makvandi, Chi-Chang Weng, et al.. (2019). Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [18F]FLT and [18F]ISO-1 PET/CT. Clinical Cancer Research. 25(10). 3063–3073. 25 indexed citations

Ellison, Paul A., Aeli P. Olson, Todd E. Barnhart, et al.. (2019). Improved production of 76Br, 77Br and 80mBr via CoSe cyclotron targets and vertical dry distillation. Nuclear Medicine and Biology. 80-81. 32–36. 23 indexed citations

10.

Weng, Chi-Chang, Sean Carlin, Catherine Hou, et al.. (2019). Correlation analysis of [18F]ROStrace using ex vivo autoradiography and dihydroethidium fluorescent imaging in lipopolysaccharide-treated animals. Biochemical and Biophysical Research Communications. 516(2). 397–401. 7 indexed citations

11.

Lee, Hwan, Aladdin Riad, Adam J. Mansfield, et al.. (2019). PARP-1–Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma. Journal of Nuclear Medicine. 61(6). 850–856. 29 indexed citations

12.

Riad, Aladdin, Chenbo Zeng, Chi-Chang Weng, et al.. (2018). Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex. Scientific Reports. 8(1). 16845–16845. 97 indexed citations

13.

Reilly, Sean W., Mehran Makvandi, Kuiying Xu, & Robert H. Mach. (2018). Rapid Cu-Catalyzed [²¹¹At]Astatination and [¹²⁵I]Iodination of Boronic Esters at Room Temperature. Organic Letters. 20(7). 1752–1755. 72 indexed citations

14.

Reilly, Sean W., Laura N. Puentes, Alexander Schmitz, et al.. (2018). Synthesis and evaluation of an AZD2461 [18F]PET probe in non-human primates reveals the PARP-1 inhibitor to be non-blood-brain barrier penetrant. Bioorganic Chemistry. 83. 242–249. 18 indexed citations

15.

Makvandi, Mehran, Lilie L. Lin, Kuiying Xu, et al.. (2017). PARP-1 Expression Quantified by [ ¹⁸ F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy. Cancer Biotherapy and Radiopharmaceuticals. 32(1). 9–15. 22 indexed citations

16.

Makvandi, Mehran, Kuiying Xu, Brian P. Lieberman, et al.. (2016). A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy. Cancer Research. 76(15). 4516–4524. 80 indexed citations

17.

Chan, Ho Sze, Mark Konijnenberg, Mehran Makvandi, et al.. (2016). Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine. EJNMMI Research. 6(1). 83–83. 54 indexed citations

18.

Makvandi, Mehran, Kuiying Xu, Brian P. Lieberman, et al.. (2016). Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo. Nuclear Medicine and Biology. 43(12). 752–758. 30 indexed citations

19.

Lieberman, Brian P., et al.. (2016). Comparative evaluation of 4 and 6-carbon spacer conformationally flexible tetrahydroisoquinolinyl benzamide analogues for imaging the sigma-2 receptor status of solid tumors. Nuclear Medicine and Biology. 43(11). 721–731. 15 indexed citations

20.

Makvandi, Mehran, Brian P. Lieberman, Chenbo Zeng, et al.. (2015). The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer. Biochemical and Biophysical Research Communications. 467(4). 1070–1075. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact